Results 211 to 220 of about 746,752 (291)

Transcription Factor HOXC11 Drives Colorectal Cancer Progression and Metastasis via CAMK2A‐Dependent CXCL5 Upregulation

open access: yesAdvanced Science, Volume 13, Issue 62, 9 November 2026.
HOXC11 drives colorectal cancer progression by transcriptionally activating CAMK2A, which triggers NF‐κB–dependent CXCL5 upregulation. CXCL5–CXCR2 signaling further reinforces HOXC11 expression through the ERK1/2–SP1 axis, forming a prometastatic positive feedback loop that is effectively disrupted by combined CAMK2A and CXCR2 inhibition.
Qingyang Sun   +12 more
wiley   +1 more source

Receptor Co‑targeting Strategies for Personalized Ovarian Cancer Therapy. [PDF]

open access: yesInt J Nanomedicine
Rajapaksha W   +6 more
europepmc   +1 more source

Targeting the PHB2–ACSL3 Lipid‐Remodeling Axis Overcomes Cisplatin Resistance by Restoring Ferroptosis in Gastric Cancer

open access: yesAdvanced Science, Volume 13, Issue 63, 12 November 2026.
ABSTRACT Platinum‐based chemotherapy resistance remains a major obstacle in gastric cancer (GC) treatment. Through integrated transcriptomic profiling of cisplatin‐resistant xenografts and pharmacogenomic interrogation of the NCI‐60 dataset, we identified Prohibitin‐2 (PHB2) as a previously unrecognized determinant of chemoresistance.
Liang Xu   +10 more
wiley   +1 more source

Selected Chemokines as Prognostic Biomarkers and Therapeutic Targets in Ovarian Cancer. [PDF]

open access: yesCurr Issues Mol Biol
Długaszek A   +7 more
europepmc   +1 more source

Expert Perspectives: Defining and Managing Progressive Pulmonary Fibrosis in Systemic Sclerosis

open access: yesArthritis &Rheumatology, Volume 78, Issue 11, Page 2189-2202, November 2026.
Systemic sclerosis–associated interstitial lung disease (SSc‐ILD) is one of the leading causes of morbidity and mortality in SSc, affecting up to three‐quarters of patients. The disease course is highly heterogeneous, ranging from indolent, nonprogressive forms to rapidly progressive pulmonary fibrosis (PPF).
Devis Benfaremo   +7 more
wiley   +1 more source

Monitoring pharmacodynamic and molecular drug targets in liquid biopsy: Exploratory study in liver cancer with modelling of EGFR Receptor engagement

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 11, Page 3902-3913, November 2026.
Abstract Aim Liquid biopsy is minimally invasive (compared with tissue biopsy) and has previously been used to generate systems data regarding drug elimination via hepatic enzymes and transporters. This study extends quantitative assessment of systems parameters in liquid biopsy to pharmacodynamic (PD) and disease markers relevant to cancer development
Zubida M. Al‐Majdoub   +3 more
wiley   +1 more source

Further Insights Into the Mechanisms of Lymph Node Metastasis

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Metastasis of malignant tumors arising from epithelial organs to sentinel lymph nodes has important implications for prognosis, staging, and therapeutic decision‐making. Recent insights into anatomic pathways, pathogenesis, molecular interactions, and genetic factors have encouraged scientists and clinicians to develop drugs that target ...
S. David Nathanson   +5 more
wiley   +1 more source

Neoadjuvant chemotherapy interferes with tertiary lymphoid structure formation in Epstein-Barr virus-associated gastric cancer. [PDF]

open access: yesNat Commun
Bi J   +13 more
europepmc   +1 more source

Intravenous Lipopolysaccharide Challenge in Healthy Participants Reveals Pharmacodynamic Markers in Blood and Bone Marrow for Early‐Phase Oncology Drug Development

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1301-1314, November 2026.
Demonstrating pharmacological effects in early‐phase oncology clinical trials remains challenging, largely due to the lack of robust pharmacodynamic markers. Lipopolysaccharide (LPS) is used as an immune challenge agent in healthy participants to study drugs for autoimmune conditions.
Igor Radanović   +11 more
wiley   +1 more source

Quercetin and Cardiovascular Health: An Evidence‐Based Review of Risk Factors and Treatments

open access: yesFood Science &Nutrition, Volume 14, Issue 11, November 2026.
Quercetin is a naturally occurring polyphenolic phytochemical distributed in fruits and vegetables. Quercetin, as a flavonoid, showed significant antioxidant capabilities and potential therapeutic effects on CVD risk factors. Quercetin reduces cardiac hypertrophy and apoptosis in cardiomyocytes by modulating critical signaling pathways.
Mohammad Reza Khazdair   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy